Credit Suisse First Boston maintained a "neutral" rating on Pfizer (nyse: PFE - news - people ) after the pharmaceuticals giant announced it would acquire Vicuron (nasdaq: MICU - news - people ) for $1.9 billion in cash. "Vicuron is developing anti-infectives for hospital and community-acquired infections, with two products currently under NDA review at the Food and Drug Administration: anidulafungin for fungal infections and dalbavancin for Gram+ infections," said CSFB. "We see the deal as strategically positive and at an acceptable valuation." The research firm added that the deal bolsters Pfizer's presence in the anti-microbial market since its patent antifungal drug Diflucan expired in 2004 while anti-infective Zithromax is set to expire at the end of this year. CSFB maintained a $27 price target on Pfizer shares. "While the 74% premium over Vicuron's 90-day average closing share price may sound high, the stock declined materially after the delay of anidulafungin," said CSFB. "The premium over Vicuron's highest historical closing price on Jan. 16 is a much more reasonable 21%." CSFB said Pfizer's plan to repatriate $28 billion dollars supports acquisitions of this size and expects to "continue to see transactions of this nature from Pfizer going forward."